Page 34 - Read Online
P. 34

Brooks et al. Rare Dis Orphan Drugs J 2024;3:15  https://dx.doi.org/10.20517/rdodj.2023.27  Page 5 of 14

               information. The existence of the GARD website is in response to the Rare Diseases Act of 2002. The Act
               requires “…the establishment of a centralized clearinghouse for rare and genetic disease information that
               will provide understandable information about these diseases to the public, medical professionals, patients
               and families”. The public can also submit inquiries to GARD.


               Patients, family members, and caregivers may contact GARD by using our online contact form or by phone.
               GARD Information Specialists provide personalized responses that are free of charge, understandable, and
               confidential.


               Because the scientific understanding of individual rare diseases increases every day, it is challenging to stay
               up to date on each disease. To address this public health challenge, GARD aims to continually provide
               updated understandable information by modernizing different approaches to this website.


               Over the past three years, the GARD website has been undergoing a major redevelopment effort in terms of
               technology, content, and user experience. A soft launch of the new site was released in the Fall of 2021, and
               NCATS has been routinely releasing new versions since then.

               The goals of the redevelopment include:


               • Enhancing user experience.


               • Modernizing website design and architecture.

               • Expanding the number of diseases covered.


               • Expanding the content available for each disease.

               • Assisting patients and caregivers in traversing the diagnostic odyssey.


               • Providing patients and caregivers with calls to actions.

               A key focus of ongoing and future development of GARD will include harmonizing data received from
               ontology providers such as Orphanet, MONDO (mondo.monarchinitiative.org), and Online Mendelian
               Inheritance in Man (OMIM).

               In addition to supporting GARD, DRDRI staff members also participate in collaborative rare disease
               informatics research on topics including rare disease epidemiology  and artificial intelligence .
                                                                       [6]
                                                                                             [7]
               NCATS toolkit for patient-focused therapy development
               The purpose of the NCATS Toolkit for Patient-Focused Therapy Development (NCATS Toolkit) is to
               educate and empower patient advocacy groups to accelerate research toward effective treatments for their
               disease by enabling their engagement as research partners. This website was created in response to requests
               from rare disease patient groups for a repository of resources to help new patient groups become more
               involved in the development of rare therapies. To coordinate with the larger rare disease community and
               avoid duplication of efforts, NCATS Toolkit links to existing resources made by and for the patient
               advocacy group community, especially umbrella rare disease patient advocacy groups. NCATS Toolkit
   29   30   31   32   33   34   35   36   37   38   39